- Home
- BROS vs ROIV Comparison
BROS vs ROIV Comparison
Compare BROS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BROS | ROIV |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 20.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BROS | ROIV |
|---|---|---|
| Price | $50.09 | $27.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $77.33 | $27.56 |
| AVG Volume (30 Days) | 3.9M | ★ 4.5M |
| Earning Date | 05-06-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.24 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $1,638,159,000.00 | $29,053,000.00 |
| Revenue This Year | $27.28 | N/A |
| Revenue Next Year | $23.02 | $594.84 |
| P/E Ratio | $79.23 | ★ N/A |
| Revenue Growth | ★ 27.88 | N/A |
| 52 Week Low | $46.52 | $8.73 |
| 52 Week High | $77.88 | $30.33 |
Technical Indicators
Market Signals| Indicator | BROS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 49.52 |
| Support Level | $46.92 | $26.94 |
| Resistance Level | $59.82 | $27.94 |
| Average True Range (ATR) | 2.27 | 0.96 |
| MACD | 0.14 | -0.38 |
| Stochastic Oscillator | 36.70 | 18.54 |
Price Performance
Historical ComparisonAbout BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.